Decay in survival motor neuron and plastin 3 levels during differentiation of iPSC-derived human motor neurons

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Boza Morán, María G ^a   Martínez Hernández, Rebeca ^a,b   Bernal, Sara ^b   Wanisch, Klaus ^a   Also Rallo, Eva ^b   Le Heron, Anita ^a   Alías, Laura ^b   Denis, Cécile ^c   Girard, Mathilde ^c   Yee, Jiing Kuan ^d   Tizzano, Eduardo F ^b,e   Yáñez Muñoz, Rafael J ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c I Stem   (France)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN BINDING PROTEIN; BIOLOGICAL MARKER; MEMBRANE PROTEIN; PLASTIN; SMN1 PROTEIN, HUMAN; SURVIVAL MOTOR NEURON PROTEIN 1;

ANIMAL; CELL CLONE; CELL DIFFERENTIATION; CELL SURVIVAL; COCULTURE; CYTOLOGY; FEMALE; HUMAN; INDUCED PLURIPOTENT STEM CELL; MALE; METABOLISM; MOTONEURON; MOUSE; NEURITE; PATHOLOGY; PEDIGREE; SKELETAL MUSCLE CELL;

ANIMALS; BIOMARKERS; CELL DIFFERENTIATION; CELL SURVIVAL; CLONE CELLS; COCULTURE TECHNIQUES; FEMALE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICROFILAMENT PROTEINS; MOTOR NEURONS; MUSCLE FIBERS, SKELETAL; NEURITES; PEDIGREE; SURVIVAL OF MOTOR NEURON 1 PROTEIN;

EID: 84933576365     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11696     Document Type: Article

References (78)

1. Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155-165, doi: 0092-8674(95)90460-3 (1995).
2. Lefebvre, S. et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 16, 265-269, doi: 10.1038/ng0797-265 (1997).
3. Buchthal, F. & Olsen, P. Z. Electromyography and muscle biopsy in infantile spinal muscular atrophy. Brain 93, 15-30 (1970).
4. Emery, A. E. et al. International collaborative study of the spinal muscular atrophies. Part 1. Analysis of clinical and laboratory data. J Neurol Sci 29, 83-94 (1976).
5. Munsat, T. L. International SMA collaboration. (26-28 June 1992, Bonn, Germany). Neuromuscul Disord 2, 423-428 (1992).
6. Russman, B. S. Spinal muscular atrophy: clinical classification and disease heterogeneity. J Child Neurol 22, 946-951, doi: 10.1177/0883073807305673 (2007).
7. Lorson, C. L. et al. SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat Genet 19, 63-66, doi: 10.1038/ng0598-63 (1998).
8. Lorson, C. L. & Androphy, E. J. An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum Mol Genet 9, 259-265, doi: ddd018 (2000).
9. Lorson, C. L., Hahnen, E., Androphy, E. J. & Wirth, B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 96, 6307-6311 (1999).
10. Soler-Botija, C. et al. Implication of fetal SMN2 expression in type I SMA pathogenesis: protection or pathological gain of function? J Neuropathol Exp Neurol 64, 215-223 (2005).
11. Hamilton, G. & Gillingwater, T. H. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med 19, 40-50, doi: 10.1016/j.molmed.2012.11.002 (2013).
12. Sleigh, J. N., Gillingwater, T. H. & Talbot, K. The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy. Dis Model Mech 4, 457-467, doi: 10.1242/dmm.007245 (2011).
13. Feldkotter, M., Schwarzer, V., Wirth, R., Wienker, T. F. & Wirth, B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 70, 358-368, doi: 10.1086/338627 (2002).
14. Wirth, B. et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet 119, 422-428, doi: 10.1007/s00439-006-0156-7 (2006).
15. Cusco, I. et al. SMN2 copy number predicts acute or chronic spinal muscular atrophy but does not account for intrafamilial variability in siblings. J Neurol 253, 21-25, doi: 10.1007/s00415-005-0912-y (2006).
16. Cobben, J. M. et al. Deletions of the survival motor neuron gene in unaffected siblings of patients with spinal muscular atrophy. Am J Hum Genet 57, 805-808 (1995).
17. Hahnen, E. et al. Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of the SMN gene in unaffected individuals. Hum Mol Genet 4, 1927-1933 (1995).
18. Capon, F. et al. Discordant clinical outcome in type III spinal muscular atrophy sibships showing the same deletion pattern. Neuromuscul Disord 6, 261-264, doi: 0960896696003501 (1996).
19. Wang, C. H. et al. Characterization of survival motor neuron (SMNT) gene deletions in asymptomatic carriers of spinal muscular atrophy. Hum Mol Genet 5, 359-365, doi: 5w0306 (1996).
20. Bussaglia, E., Tizzano, E. F., Illa, I., Cervera, C. & Baiget, M. Cramps and minimal EMG abnormalities as preclinical manifestations of spinal muscular atrophy patients with homozygous deletions of the SMN gene. Neurology 48, 1443-1445 (1997).
21. Cusco, I. et al. A genetic and phenotypic analysis in Spanish spinal muscular atrophy patients with c.399-402del AGAG, the most frequently found subtle mutation in the SMN1 gene. Hum Mutat 22, 136-143, doi: 10.1002/humu.10245 (2003).
22. Oprea, G. E. et al. Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science 320, 524-527, doi: 10.1126/science.1155085 (2008).
23. Stratigopoulos, G. et al. Association of plastin 3 expression with disease severity in spinal muscular atrophy only in postpubertal females. Arch Neurol 67, 1252-1256, doi: 10.1001/archneurol.2010.239 (2010).
24. Yanyan, C. et al. Correlation of PLS3 expression with disease severity in children with spinal muscular atrophy. J Hum Genet 59, 24-27, doi: 10.1038/jhg.2013.111 (2014).
25. Bernal, S. et al. Plastin 3 expression in discordant spinal muscular atrophy (SMA) siblings. Neuromuscul Disord 21, 413-419, doi: 10.1016/j.nmd.2011.03.009 (2011).
26. Bussaglia, E. et al. A frame-shift deletion in the survival motor neuron gene in Spanish spinal muscular atrophy patients. Nat Genet 11, 335-337, doi: 10.1038/ng1195-335 (1995).
27. Ebert, A. D. et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457, 277-280, doi: 10.1038/ nature07677 (2009).
28. Sareen, D. et al. Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy. PLoS One 7, e39113, doi: 10.1371/journal.pone.0039113 (2012).
29. Chang, T. et al. Brief report: phenotypic rescue of induced pluripotent stem cell-derived motoneurons of a spinal muscular atrophy patient. Stem Cells 29, 2090-2093, doi: 10.1002/stem.749 (2011).
30. Corti, S. et al. Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci Transl Med 4, 165ra162, doi: 10.1126/scitranslmed.3004108 (2012).
31. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872, doi: 10.1016/j.cell.2007.11.019 (2007).
32. Hu, B. Y. & Zhang, S. C. Differentiation of spinal motor neurons from pluripotent human stem cells. Nat Protoc 4, 1295-1304, doi: 10.1038/nprot.2009.127 (2009).
33. Lee, S. K., Jurata, L. W., Funahashi, J., Ruiz, E. C. & Pfaff, S. L. Analysis of embryonic motoneuron gene regulation: derepression of general activators function in concert with enhancer factors. Development 131, 3295-3306, doi: 10.1242/dev.01179 (2004).
34. Marchetto, M. C. et al. Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell 3, 649-657, doi: 10.1016/j.stem.2008.10.001 (2008).
35. Hester, M. E. et al. Rapid and efficient generation of functional motor neurons from human pluripotent stem cells using gene delivered transcription factor codes. Mol Ther 19, 1905-1912, doi: 10.1038/mt.2011.135 (2011).
36. Li, X. J. et al. Directed differentiation of ventral spinal progenitors and motor neurons from human embryonic stem cells by small molecules. Stem Cells 26, 886-893, doi: 10.1634/stemcells.2007-0620 (2008).
37. Also-Rallo, E. et al. Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter-and intra-patient variability. Eur J Hum Genet 19, 1059-1065, doi: 10.1038/ejhg.2011.89 (2011).
38. Maury, Y. et al. Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes. Nat Biotechnol 33, 89-96, doi: 10.1038/nbt.3049 (2015).
39. McGivern, J. V. et al. Spinal muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor production. Glia 61, 1418-1428, doi: 10.1002/glia.22522 (2013).
40. Dominguez, E. et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet 20, 681-693, doi: 10.1093/hmg/ddq514 (2011).
41. Foust, K. D. et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 28, 271-274, doi: 10.1038/nbt.1610 (2010).
42. Lee, A. J., Awano, T., Park, G. H. & Monani, U. R. Limited phenotypic effects of selectively augmenting the SMN protein in the neurons of a mouse model of severe spinal muscular atrophy. PLoS One 7, e46353, doi: 10.1371/journal.pone.0046353 (2012).
43. Martinez, T. L. et al. Survival motor neuron protein in motor neurons determines synaptic integrity in spinal muscular atrophy. J Neurosci 32, 8703-8715, doi: 10.1523/JNEUROSCI.0204-12.2012 (2012).
44. Martinez-Hernandez, R. et al. Synaptic defects in type I spinal muscular atrophy in human development. J Pathol 229, 49-61, doi: 10.1002/path.4080 (2013).
45. Thomson, S. R., Wishart, T. M., Patani, R., Chandran, S. & Gillingwater, T. H. Using induced pluripotent stem cells (iPSC) to model human neuromuscular connectivity: promise or reality? J Anat 220, 122-130, doi: 10.1111/j.1469-7580.2011.01459.x (2012).
46. Jablonka, S., Schrank, B., Kralewski, M., Rossoll, W. & Sendtner, M. Reduced survival motor neuron (Smn) gene dose in mice leads to motor neuron degeneration: an animal model for spinal muscular atrophy type III. Hum Mol Genet 9, 341-346, doi: ddd051 (2000).
47. Jablonka, S. et al. Co-regulation of survival of motor neuron (SMN) protein and its interactor SIP1 during development and in spinal muscular atrophy. Hum Mol Genet 10, 497-505 (2001).
48. La Bella, V., Cisterni, C., Salaun, D. & Pettmann, B. Survival motor neuron (SMN) protein in rat is expressed as different molecular forms and is developmentally regulated. Eur J Neurosci 10, 2913-2923 (1998).
49. Gabanella, F., Carissimi, C., Usiello, A. & Pellizzoni, L. The activity of the spinal muscular atrophy protein is regulated during development and cellular differentiation. Hum Mol Genet 14, 3629-3642, doi: 10.1093/hmg/ddi390 (2005).
50. Pagliardini, S. et al. Subcellular localization and axonal transport of the survival motor neuron (SMN) protein in the developing rat spinal cord. Hum Mol Genet 9, 47-56, doi: ddd013 (2000).
51. Tizzano, E. F., Cabot, C. & Baiget, M. Cell-specific survival motor neuron gene expression during human development of the central nervous system: implications for the pathogenesis of spinal muscular atrophy. Am J Pathol 153, 355-361, doi: 10.1016/ S0002-9440(10)65578-2 (1998).
52. Novelli, G. et al. Expression study of survival motor neuron gene in human fetal tissues. Biochem Mol Med 61, 102-106, doi: S1077315097925904 (1997).
53. Rossoll, W. et al. Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of betaactin mRNA in growth cones of motoneurons. J Cell Biol 163, 801-812, doi: 10.1083/jcb.200304128 (2003).
54. Jablonka, S., Beck, M., Lechner, B. D., Mayer, C. & Sendtner, M. Defective Ca2+ channel clustering in axon terminals disturbs excitability in motoneurons in spinal muscular atrophy. J Cell Biol 179, 139-149, doi: 10.1083/jcb.200703187 (2007).
55. Hao le, T. et al. Temporal requirement for SMN in motoneuron development. Hum Mol Genet 22, 2612-2625, doi: 10.1093/hmg/ ddt110 (2013).
56. Shafey, D., MacKenzie, A. E. & Kothary, R. Neurodevelopmental abnormalities in neurosphere-derived neural stem cells from SMN-depleted mice. J Neurosci Res 86, 2839-2847, doi: 10.1002/jnr.21743 (2008).
57. McWhorter, M. L., Monani, U. R., Burghes, A. H. & Beattie, C. E. Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. J Cell Biol 162, 919-931, doi: 10.1083/jcb.200303168 (2003).
58. Ymlahi-Ouazzani, Q. et al. Reduced levels of survival motor neuron protein leads to aberrant motoneuron growth in a Xenopus model of muscular atrophy. Neurogenetics 11, 27-40, doi: 10.1007/s10048-009-0200-6 (2010).
59. Soler-Botija, C., Ferrer, I., Gich, I., Baiget, M. & Tizzano, E. F. Neuronal death is enhanced and begins during foetal development in type I spinal muscular atrophy spinal cord. Brain 125, 1624-1634 (2002).
60. Soler-Botija, C., Ferrer, I., Alvarez, J. L., Baiget, M. & Tizzano, E. F. Downregulation of Bcl-2 proteins in type I spinal muscular atrophy motor neurons during fetal development. J Neuropathol Exp Neurol 62, 420-426 (2003).
61. Martinez-Hernandez, R. et al. The developmental pattern of myotubes in spinal muscular atrophy indicates prenatal delay of muscle maturation. J Neuropathol Exp Neurol 68, 474-481, doi: 10.1097/NEN.0b013-3181a10ea1 (2009).
62. Germain-Desprez, D. et al. The SMN genes are subject to transcriptional regulation during cellular differentiation. Gene 279, 109-117, doi: S0378-1119(01)00758-2 (2001).
63. Wang, Z. B., Zhang, X. & Li, X. J. Recapitulation of spinal motor neuron-specific disease phenotypes in a human cell model of spinal muscular atrophy. Cell Res 23, 378-393, doi: 10.1038/cr.2012.166 (2013).
64. Crawford, T. O. et al. Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PLoS One 7, e33572, doi: 10.1371/journal.pone.0033572 (2012).
65. Ackermann, B. et al. Plastin 3 ameliorates spinal muscular atrophy via delayed axon pruning and improves neuromuscular junction functionality. Hum Mol Genet 22, 1328-1347, doi: 10.1093/hmg/dds540 (2013).
66. Hao le, T., Wolman, M., Granato, M. & Beattie, C. E. Survival motor neuron affects plastin 3 protein levels leading to motor defects. J Neurosci 32, 5074-5084, doi: 10.1523/JNEUROSCI.5808-11.2012 (2012).
67. Sumner, C. J. et al. SMN mRNA and protein levels in peripheral blood: biomarkers for SMA clinical trials. Neurology 66, 1067-1073, doi: 10.1212/01.wnl.0000201929.56928.13 (2006).
68. Tiziano, F. D. et al. Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study. Eur J Hum Genet 21, 630-636, doi: 10.1038/ejhg.2012.233 (2013).
69. Tiziano, F. D. et al. SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. Eur J Hum Genet 18, 52-58, doi: 10.1038/ejhg.2009.116 (2010).
70. Kolb, S. J. et al. A novel cell immunoassay to measure survival of motor neurons protein in blood cells. Neurol 6, 6, doi: 10.1186/1471-2377-6-6 (2006).
71. Vezain, M. et al. A sensitive assay for measuring SMN mRNA levels in peripheral blood and in muscle samples of patients affected with spinal muscular atrophy. Eur J Hum Genet 15, 1054-1062, doi: 10.1038/sj.ejhg.5201885 (2007).
72. Simard, L. R. et al. Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with SMA. Neurology 68, 451-456, doi: 10.1212/01.wnl.0000252934.70676.ab (2007).
73. Jedrzejowska, M. et al. Unaffected patients with a homozygous absence of the SMN1 gene. Eur J Hum Genet 16, 930-934, doi: 10.1038/ejhg.2008.41 (2008).
74. Zerres, K. & Rudnik-Schoneborn, S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol 52, 518-523 (1995).
75. Yáñez-Muñoz, R. J. et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 12, 348-353, doi: 10.1038/ nm1365 (2006).
76. Mangeot, P. E. et al. Protein transfer into human cells by VSV-G-induced nanovesicles. Mol Ther 19, 1656-1666, doi: 10.1038/ mt.2011.138 (2011).
77. Park, I. H. et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451, 141-146, doi: 10.1038/ nature06534 (2008).
78. Vandesompele, J. et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Biol 3, RESEARCH0034 (2002).